AFP and hepatocellular carcinoma: Between 2011 and 2020, the proportion of patients with NBNC-HCC increased (which would have led to a decreasing trend in AFP elevation), which was counterbalanced by the decreased proportion of patients with BCLC stages 0–A HCC (which would have led to an increasing trend in AFP elevation).